Zevra Grants 53,000 Stock Options to Attract New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Should l Buy ZVRA?
Source: Newsfilter
- Employee Incentive Program: Zevra Therapeutics has granted a total of 53,000 stock options to three new employees under its 2023 Employment Inducement Award Plan, aimed at attracting talent and enhancing the company's competitive edge in rare disease treatment.
- Option Grant Details: Each stock option vests over four years, with 25% vesting in the first year and the remainder in three equal annual installments, which not only incentivizes long-term employee retention but also enhances team stability.
- Compliance Assurance: The stock option grants comply with Nasdaq Rule 5635(c)(4), ensuring that the company adheres to relevant regulations while attracting new employees, thereby reducing legal risks and boosting investor confidence.
- Mission Reinforcement: Zevra focuses on providing therapies for rare disease patients, and this incentive measure not only helps attract skilled professionals but also drives the company's innovative capabilities in complex drug development, furthering its mission.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZVRA
Wall Street analysts forecast ZVRA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.930
Low
21.00
Averages
24.00
High
26.00
Current: 8.930
Low
21.00
Averages
24.00
High
26.00
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zevra Therapeutics Appoints New CFO
- Executive Appointment: Zevra Therapeutics announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026, bringing a wealth of financial strategy experience to the company.
- Industry Background: Renz most recently served as CFO and COO at Ardelyx, where he played a key role in the launch and commercialization of two innovative medicines, indicating his successful track record in the pharmaceutical market will benefit Zevra's future.
- Past Achievements: While at Correvio Pharma, Renz was president and CFO, overseeing the commercialization of two cardiovascular and two infectious disease products, demonstrating his capability in driving product launches.
- Diverse Career Experience: Renz has held executive roles at Karyopharm Pharmaceuticals and Zalicus, accumulating extensive experience in financial management and strategic planning, which will support Zevra's financial health and market competitiveness.
See More
Zevra Therapeutics Appoints New CFO
- Executive Appointment: Zevra Therapeutics announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026, indicating a strategic move in enhancing its financial leadership.
- Extensive Experience: Renz brings over 25 years of financial leadership experience in the biopharmaceutical industry, particularly in capital markets, strategic transactions, and commercial operations, which will provide Zevra with valuable industry insights.
- Previous Roles: Prior to joining Zevra, Renz served as Chief Financial & Operations Officer at Ardelyx, showcasing a successful track record in executive roles that is expected to bolster Zevra's financial stability.
- Background: Renz has also held positions as President and CFO at Correvio Pharma, and as Executive Vice President at Karyopharm Pharmaceuticals and Zalicus Inc., with his extensive background poised to enhance Zevra's financial performance in a competitive market.
See More
Zevra Therapeutics Appoints New CFO Justin Renz to Drive Growth
- Executive Appointment: Zevra Therapeutics announced the appointment of Justin Renz as Chief Financial Officer effective March 9, 2026, bringing over 25 years of financial leadership experience in the biopharmaceutical industry, which is expected to enhance the company's strategic plan and market position in rare diseases.
- Financial Leadership: Renz's previous role as Chief Financial & Operations Officer at Ardelyx involved active participation in the launch and commercialization of two innovative medicines, showcasing his strong background in capital markets and strategic transactions, which will provide robust support for Zevra's financial foundation.
- Industry Experience: Prior to joining Zevra, Renz served as President and CFO of Correvio Pharma, focusing on the commercialization of cardiovascular and infectious disease products, indicating his successful track record in driving company growth and creating shareholder value.
- Educational Background: Renz holds a B.A. in Economics and Accounting, an M.S. in Taxation, and an M.B.A., along with being a Certified Public Accountant in Massachusetts, demonstrating his solid professional knowledge and industry recognition, which will underpin Zevra's innovation and market expansion efforts.
See More
Zevra Therapeutics to Report Q4 and Full Year 2025 Results
- Earnings Announcement: Zevra Therapeutics will report its fourth quarter and full year 2025 financial results on March 9, 2026, after market close, highlighting the company's ongoing progress in rare disease therapies.
- Conference Call Details: The company will host a conference call at 4:30 PM ET on the same day, providing investors with an opportunity for direct interaction with management, thereby enhancing transparency and boosting investor confidence.
- Webcast Access: Investors can access the audio webcast via the 'Events & Presentations' page on Zevra's website, ensuring broad dissemination and access to information, which further elevates the company's visibility among investors.
- Company Overview: Zevra Therapeutics focuses on providing therapies for rare disease patients, with its lead product recognized in the U.S. market, demonstrating the company's commercialization capabilities and market potential in the rare disease sector.
See More
Zevra Presents Positive Data on MIPLYFFA for Niemann-Pick Disease at World Symposium
- Clinical Data Highlights: Zevra showcased positive data on MIPLYFFA (arimoclomol) for Niemann-Pick Disease Type C at the 22nd Annual World Symposium, indicating that four years of real-world data demonstrate effective stabilization of disease progression, with clinical severity score changes remaining below clinically meaningful thresholds, showcasing sustained benefits across a broad patient population.
- Long-term Efficacy Analysis: Multi-year subgroup analyses from the U.S. Early Access Program reveal that patients treated with arimoclomol exhibited durable treatment effects over up to four years of follow-up, supporting sustained clinical benefits with continued use, particularly providing crucial clinical data in the adult patient population.
- Randomized Controlled Trial Results: In the randomized, double-blind, placebo-controlled NPC002 trial, arimoclomol combined with miglustat demonstrated statistically significant slowing of disease progression as early as three months post-treatment initiation, with sustained benefits increasing through 12 months, highlighting early clinical effects in patients with Niemann-Pick Disease.
- Safety and Effectiveness: Adult patients treated with arimoclomol in the U.S. Early Access Program showed disease stabilization over four years while maintaining a favorable safety profile, providing the most robust insights to date into this understudied adult NPC population and marking the first published evidence of arimoclomol's impact in adult patients.
See More
Zevra Therapeutics Invited to Ring Nasdaq Opening Bell
- Nasdaq Opening Ceremony: Zevra Therapeutics is invited to ring the Nasdaq opening bell on February 9, 2026, with CEO Neil F. McFarlane delivering remarks at 9:24 a.m., marking the start of the trading day and enhancing the company's visibility among investors.
- Product Commercialization Progress: The company's lead product is marketed in the U.S. for Niemann-Pick disease type C, establishing a strong foundation and validating its capability to advance therapies, showcasing its market potential in the rare disease sector.
- Geographic Expansion Opportunities: Zevra is broadening access through geographic expansion, which will help increase market share and provide necessary treatments to more patients, thereby enhancing the company's sense of social responsibility.
- Patient-Centric Philosophy: Zevra is committed to creating long-term value for patients, partners, and shareholders through innovation and accountability, a philosophy that will drive the company's continued growth in the future.
See More
Zevra Therapeutics Appoints New CFO
- Executive Appointment: Zevra Therapeutics announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026, bringing a wealth of financial strategy experience to the company.
- Industry Background: Renz most recently served as CFO and COO at Ardelyx, where he played a key role in the launch and commercialization of two innovative medicines, indicating his successful track record in the pharmaceutical market will benefit Zevra's future.
- Past Achievements: While at Correvio Pharma, Renz was president and CFO, overseeing the commercialization of two cardiovascular and two infectious disease products, demonstrating his capability in driving product launches.
- Diverse Career Experience: Renz has held executive roles at Karyopharm Pharmaceuticals and Zalicus, accumulating extensive experience in financial management and strategic planning, which will support Zevra's financial health and market competitiveness.
See More
Zevra Therapeutics Appoints New CFO
- Executive Appointment: Zevra Therapeutics announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026, indicating a strategic move in enhancing its financial leadership.
- Extensive Experience: Renz brings over 25 years of financial leadership experience in the biopharmaceutical industry, particularly in capital markets, strategic transactions, and commercial operations, which will provide Zevra with valuable industry insights.
- Previous Roles: Prior to joining Zevra, Renz served as Chief Financial & Operations Officer at Ardelyx, showcasing a successful track record in executive roles that is expected to bolster Zevra's financial stability.
- Background: Renz has also held positions as President and CFO at Correvio Pharma, and as Executive Vice President at Karyopharm Pharmaceuticals and Zalicus Inc., with his extensive background poised to enhance Zevra's financial performance in a competitive market.
See More
Zevra Therapeutics Appoints New CFO Justin Renz to Drive Growth
- Executive Appointment: Zevra Therapeutics announced the appointment of Justin Renz as Chief Financial Officer effective March 9, 2026, bringing over 25 years of financial leadership experience in the biopharmaceutical industry, which is expected to enhance the company's strategic plan and market position in rare diseases.
- Financial Leadership: Renz's previous role as Chief Financial & Operations Officer at Ardelyx involved active participation in the launch and commercialization of two innovative medicines, showcasing his strong background in capital markets and strategic transactions, which will provide robust support for Zevra's financial foundation.
- Industry Experience: Prior to joining Zevra, Renz served as President and CFO of Correvio Pharma, focusing on the commercialization of cardiovascular and infectious disease products, indicating his successful track record in driving company growth and creating shareholder value.
- Educational Background: Renz holds a B.A. in Economics and Accounting, an M.S. in Taxation, and an M.B.A., along with being a Certified Public Accountant in Massachusetts, demonstrating his solid professional knowledge and industry recognition, which will underpin Zevra's innovation and market expansion efforts.
See More
Zevra Therapeutics to Report Q4 and Full Year 2025 Results
- Earnings Announcement: Zevra Therapeutics will report its fourth quarter and full year 2025 financial results on March 9, 2026, after market close, highlighting the company's ongoing progress in rare disease therapies.
- Conference Call Details: The company will host a conference call at 4:30 PM ET on the same day, providing investors with an opportunity for direct interaction with management, thereby enhancing transparency and boosting investor confidence.
- Webcast Access: Investors can access the audio webcast via the 'Events & Presentations' page on Zevra's website, ensuring broad dissemination and access to information, which further elevates the company's visibility among investors.
- Company Overview: Zevra Therapeutics focuses on providing therapies for rare disease patients, with its lead product recognized in the U.S. market, demonstrating the company's commercialization capabilities and market potential in the rare disease sector.
See More
Zevra Presents Positive Data on MIPLYFFA for Niemann-Pick Disease at World Symposium
- Clinical Data Highlights: Zevra showcased positive data on MIPLYFFA (arimoclomol) for Niemann-Pick Disease Type C at the 22nd Annual World Symposium, indicating that four years of real-world data demonstrate effective stabilization of disease progression, with clinical severity score changes remaining below clinically meaningful thresholds, showcasing sustained benefits across a broad patient population.
- Long-term Efficacy Analysis: Multi-year subgroup analyses from the U.S. Early Access Program reveal that patients treated with arimoclomol exhibited durable treatment effects over up to four years of follow-up, supporting sustained clinical benefits with continued use, particularly providing crucial clinical data in the adult patient population.
- Randomized Controlled Trial Results: In the randomized, double-blind, placebo-controlled NPC002 trial, arimoclomol combined with miglustat demonstrated statistically significant slowing of disease progression as early as three months post-treatment initiation, with sustained benefits increasing through 12 months, highlighting early clinical effects in patients with Niemann-Pick Disease.
- Safety and Effectiveness: Adult patients treated with arimoclomol in the U.S. Early Access Program showed disease stabilization over four years while maintaining a favorable safety profile, providing the most robust insights to date into this understudied adult NPC population and marking the first published evidence of arimoclomol's impact in adult patients.
See More
Zevra Therapeutics Invited to Ring Nasdaq Opening Bell
- Nasdaq Opening Ceremony: Zevra Therapeutics is invited to ring the Nasdaq opening bell on February 9, 2026, with CEO Neil F. McFarlane delivering remarks at 9:24 a.m., marking the start of the trading day and enhancing the company's visibility among investors.
- Product Commercialization Progress: The company's lead product is marketed in the U.S. for Niemann-Pick disease type C, establishing a strong foundation and validating its capability to advance therapies, showcasing its market potential in the rare disease sector.
- Geographic Expansion Opportunities: Zevra is broadening access through geographic expansion, which will help increase market share and provide necessary treatments to more patients, thereby enhancing the company's sense of social responsibility.
- Patient-Centric Philosophy: Zevra is committed to creating long-term value for patients, partners, and shareholders through innovation and accountability, a philosophy that will drive the company's continued growth in the future.
See More
